



IBD INNOVATE™

PRODUCT DEVELOPMENT FOR CROHN'S & COLITIS

**The premier IBD product development
conference for therapeutics, diagnostics,
devices, and digital health.**

April 26, 2023

Metropolitan Pavilion
New York City

bit.ly/IBD-Innovate



Welcome to IBD INNOVATE 2023!

The Crohn's & Colitis Foundation welcomes you to the 5th annual IBD INNOVATE conference.

As an extension of our venture philanthropy program, IBD Ventures, IBD INNOVATE is the premier IBD product development conference in the world highlighting novel and differentiated therapeutics, diagnostics, devices, and digital health technology with the potential to bring innovative solutions for IBD patients. This year's conference includes stellar keynotes addressing important topics including the role of epithelial barrier function as a new target for drug development, microbiome based-solutions, and a glimpse into the future of IBD therapeutics. The conference also features a poster session displaying a wide range of innovative technologies for the treatment, diagnostics, and management of IBD. In addition, one-on-one networking opportunities are available so attendees can meet and connect with key stakeholders and establish productive scientific and business collaborations.

We look forward to meeting you!

Organizing Committee



Anthony Slavin, PhD
Vice President
Kymera Therapeutics



Russell Wyborski, PhD
Director, IBD Ventures Investments
Crohn's & Colitis Foundation



Nicole Schwerbrock, PhD
Senior Manager,
IBD Ventures Investments
Crohn's & Colitis Foundation



Andrés Hurtado-Lorenzo, PhD
Vice President, Translational Research
& IBD Ventures
Crohn's & Colitis Foundation



Caren Heller, MD, MBA
Chief Scientific Officer
Crohn's & Colitis Foundation

Location

All conference programming will be held at the Metropolitan Pavilion, 125 West 18th Street, 5th floor, New York, NY. Signs will direct you to locations for registration, talks, and 1:1 meetings upon your arrival.

Registration and Event Information



bit.ly/IBD-Innovate

Social Media

Join the conversation on social media using hashtag **#Innovate23**

Contact

Program-related inquiries:

Nicole Schwerbrock
entrepreneurship@crohnscolitisfoundation.org

Sponsorship-related inquiries:

Elise Ambrose
eambrose@crohnscolitisfoundation.org
or (646) 745-4738

AGENDA

April 26, 2023

TIME	TITLE	SPEAKER	AFFILIATION
8:00–8:15 a.m.	Welcome	Andrés Hurtado-Lorenzo, PhD <i>Vice President, Translational Research & IBD Ventures</i>	Crohn's & Colitis Foundation
KEYNOTE—MUCOSAL WOUND HEALING			
8:15–9:00 a.m.	The Intestinal Barrier: Fiction, Fact, and Pharmacotherapy	Jerrold Turner, MD, PhD <i>Professor of Pathology and Medicine Harvard Medical School</i>	Harvard University Medical School
SESSION 1—MUCOSAL WOUND HEALING		Moderator: Russell Wyborski, PhD <i>Director, IBD Ventures Investments</i>	Crohn's & Colitis Foundation
9:00–9:20 a.m.	Novel Synthetic Peptide (NIPEP-IBD) Based Therapeutic Strategy by Acceleration of Mucosal Regeneration	Jue-Yeon Lee, PhD <i>Director of Research Institute of NIBEC</i>	Nano Intelligent Biomedical Engineering Corporation (NIBEC)
9:20–9:40 a.m.	IBD3540: A Gut-Restricted GCPII Inhibitor with Dual Anti-Inflammatory and Analgesic Activities	Diane Peters, DVM, PhD <i>Assistant Professor of Pharmacology and Molecular Sciences</i>	Johns Hopkins University
9:40–10:00 a.m.	The Potential of Targeting TREM-1 in Inflammatory Bowel Disease	Marc Derive, PhD <i>Co-Founder & Chief Scientific Officer</i>	INOTREM
10:00–10:20 a.m.	Assessment of Endoscopic and Histologic Findings in IBD Clinical Development: FDA Perspective	Matthew Kowalik, MD <i>Clinical Team Leader, Division of Gastroenterology</i>	The United States Food and Drug Administration (FDA)
10:20–10:40 a.m.	Defining Mucosal Healing for Ulcerative Colitis	Russell McBride, PhD, MPH <i>Assistant Professor of Pathology and Epidemiology</i>	Icahn School of Medicine at Mount Sinai
10:40–10:50 a.m.	Break		

AGENDA

April 26, 2023

TIME	TOPIC/TITLE	SPEAKER	AFFILIATION
KEYNOTE—MICROBIOME			
10:50–11:30 a.m.	Development of Microbiome-Based Medicines. A Decade of Ups and Downs	Bernat Olle, PhD, MBA <i>Chief Executive Officer at Vedanta Biosciences</i>	Vedanta Biosciences
SESSION 2—MICROBIOME		Moderator: Nicole Schwerbrock, PhD <i>Senior Manager, IBD Ventures Investments</i>	Crohn's & Colitis Foundation
11:30–11:50 a.m.	Uncovering Yesterday's Science to Disrupt Today	Zain Kassam, MD, MPH <i>Co-Founder at Finch Therapeutics & OpenBiome</i>	Formerly Finch Therapeutics CMO
11:50 a.m.–12:10 p.m.	Leveraging Interventional Studies to Drive Novel Microbiome Therapeutic Development in IBD	Chris Ford, PhD <i>Vice President, Translational Biology at Seres Therapeutics</i>	Seres Therapeutics
12:10–12:30 p.m.	Understanding the IBD Microbiome: from Diagnostics, Disease Management to Rational Design of Life Therapeutics.	Daniel van der Lelie, PhD, MBA <i>Chief Executive Officer at Gusto Global</i>	Gusto Global
12:30–12:45 p.m.	Prioritizing What Matters: Understanding the Challenges and Opportunities for IBD Patients	Rocio Castrillon, MBA	VoiceForIBD
12:45–1:15 p.m.	Lunch		
SESSION 3—DEVICES & DIAGNOSTICS		Moderator: Andrés Hurtado-Lorenzo, PhD <i>Vice President Translational Research & IBD Ventures</i>	Crohn's & Colitis Foundation
1:15–1:35 p.m.	Colonic Delivery of Therapies by a Novel Ingestible Medical Device	Chris Wahl, MD, MBA <i>Vice President, Biora</i>	Biora Therapeutics
1:35–1:55 p.m.	Adhesive Filler for Perianal Fistulas	Maria Pereira, PhD <i>Chief Innovation Officer</i>	Tissium
1:55–2:15 p.m.	IBD Aware: A Wearable Action for Real-Time Elevations in IBD Markers	Sriram Muthukumar, PhD <i>CEO and Co-Founder of EnLiSense</i>	EnLiSense

AGENDA

April 26, 2023

TIME	TOPIC/TITLE	SPEAKER	AFFILIATION
2:15–2:35 p.m.	Advances in IBD Translational Imaging: Beyond White Light Endoscopy	Annette Schwartz-Stermann, DMV, DACVP <i>Senior Director, AbbVie Immunology Discovery Research</i>	AbbVie
2:35–2:50 p.m.	Break		
KEYNOTE—FUTURE OF IBD PRODUCT DEVELOPMENT			
2:50–3:30 p.m.	Future Drug Development in IBD: Navigating Ceilings, Cliffs, and Platforms	Scott Plevy, MD <i>Executive Vice President and Therapeutic Head, Gastroenterology at Protagonist Therapeutics</i>	Protagonist Therapeutics
SESSION 4—FUTURE OF IBD PRODUCT DEVELOPMENT		Moderator: Anthony Slavin, PhD <i>Vice President at Kymera Therapeutics</i>	Kymera Therapeutics
3:30–3:50 p.m.	IBD Therapeutics Incubator: Creating New Product Opportunities to Treat IBD	Andrés Hurtado-Lorenzo, PhD <i>Vice President Translational Research & IBD Ventures</i>	Crohn's & Colitis Foundation
3:50–4:00 p.m.	IBD Plexus: Establishing a Path to Precision Medicine	Ben Kostiuk, PhD <i>Associate Director, Life Science Partnerships, IBD Plexus</i>	Crohn's & Colitis Foundation
4:00–4:30 p.m.	Panel Discussion: What Should Patients Expect?	Moderator: Anthony Slavin Panelists: * Sam Jactel, Lea Ann Chen, Jeanne Magram, Jennifer Swantek	*Various affiliations see below
4:30–4:45 p.m.	Closing Remarks	Russell Wyborski, PhD <i>Director, IBD Ventures Investments</i>	Crohn's & Colitis Foundation
4:45–7:00 p.m.	Poster Session/Networking		

***Panel presenters**

Sam Jactel, MBA

Patient, Founder and CEO of Ayble Health

Lea Ann Chen, MD

Director, Inflammatory Bowel Disease Translational Research, Rutgers Robert Wood Johnson Medical School

Jeanne Magram, PhD

Chief Scientific Officer at Celsius Therapeutics

Jennifer Swantek, PhD

Director, IBD Therapeutics Incubator at Crohn's & Colitis Foundation

POSTERS

April 26, 2023

POSTER	ORGANIZATION	CATEGORY	POSTER TITLE
1	Apexian Pharmaceuticals	Therapeutic	APE1/Ref-1 as a Novel Molecular Target for IBD Treatment: Oral, Small Molecule Inhibitor of APE1/Ref-1 Alleviates Intestinal Dysfunction and Damage to Myenteric Neurons in a Model of Spontaneous Chronic Colitis
2	BioPhammer	Therapeutic	Development of Vactosertib, a Highly Potent, Selective, and Orally Bioavailable Small Molecule TGF- β type I Receptor (ALK5)/RIPK2 Dual Inhibitor, as an Effective Anti-fibrotic IBD Agent
3	ClostraBio	Therapeutic	Novel Orally Delivered Nanoparticles for Treatment of Mild-Moderate Colitis via Intestinal Release of Butyrate
4	Coprata	Device	Automated Sampling Toilet: Improving Adherence to Fecal Calprotectin Testing
5	Giiant Pharma	Therapeutic	Giiant's Gut-Restricted Intervention Platform: Pre-Clinical Proof of Concept in Colitis with PDE4
6	Icahn School of Medicine	Microbiome	Flexible Platform for Low Cost Defined Microbiota Therapeutics
7	Immunyx Pharma	Therapeutic	Modulating Neutrophil Toxicity in IBD
8	Koutif Therapeutics	Therapeutic	A GI-Targeted Formulation of Fbxo3 Inhibitor BC-1261 for IBD
9	LAPIX Therapeutics	Therapeutic	Antigen Agnostic Immune Tolerance Restoration Therapy for the Treatment of IBD
10	LyfeMD	Digital Health	Novel Digital Health Tools Improve Clinical Outcomes in Patients with Inflammatory Bowel Disease
11	Medibiofarma	Therapeutic	MBF-118, a Novel Small Molecule Therapy in Phase II Development for Fibrosis in Crohn's Disease
12	Microbiotica	Microbiome	MB310: From Clinical FMT to a Phase 1 Study with a Defined, Orally-Administered Live Bacterial Therapeutic for Mild-Moderate Ulcerative Colitis

POSTERS

April 26, 2023

POSTER	ORGANIZATION	CATEGORY	POSTER TITLE
13	Mobius Care	Therapeutic	Personalized IBD Care: AI Pathology to Improve Standard of Care
14	New York University (NYU)	Therapeutic	The S1P Transporter SPNS2 as a Novel Target for IBD Therapy
15	Orange Grove Bio	Therapeutic	Targeting Liver Receptor Homolog-1 (LRH-1) as a Treatment for Inflammatory Bowel Disease
16	PathAI	Digital Health	Machine Learning-Based Prediction of Geboes Score and Histologic Improvement and Remission Thresholds in Ulcerative Colitis.
17	Precidiag Inc	Therapeutic	Therapeutic Development Stemming from Multi-Omic Analyses of the Ulcerative Colitis Gut Microbiome
18	PredictImmune	Diagnostic	From Concept to Care: Commercialising PredictSURE IBD
19	Virgo Pharma	Digital Health	Revolutionizing Recruitment in IBD Trials with AI and Endoscopy

This conference is generously supported, in part, by:

Our Silver Sponsors:



Our Starter Sponsors:



CROHN'S & COLITIS FOUNDATION

733 Third Avenue, Suite 510, New York, NY 10017
www.crohnscolitisfoundation.org • 800-932-2423